Program
Bupropion
Also written as “bupropion hydrochloride”, “Extended-release Bupropion Hydrochloride” and “Extended-release bupropion hydrochloride”.
Its studies are mostly in Smoking Cessation · Depressive Disorder, Major · Depressive Disorder · Seasonal Affective Disorder · Obesity, led by 6 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 80 open or running | phase 3since Sep 24, 2002 | Sep 24, 2002 | none ahead |
| Teva Pharmaceutical Industries | 60 open or running | phase 1since Mar 17, 2009 | Mar 17, 2009 | none ahead |
| Rose Research Center | 20 open or running | phase 3since May 11, 2020 | May 11, 2020 | none ahead |
| Johnson & Johnson | 10 open or running | phase 1since Oct 2, 2015 | Oct 2, 2015 | none ahead |
| Novartis | 10 open or running | phase 1since Apr 16, 2009 | Apr 16, 2009 | none ahead |
| Takeda | 10 open or running | phase 4since Nov 24, 2015 | Nov 24, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 24, 2002First study: phase 3 study in Seasonal Affective DisorderNew to GlaxoSmithKlineGlaxoSmithKline · NCT00046241 · 300 enrolled · United States, Canada
- Oct 30, 2002Phase 3 study in Attention Deficit Disorder with HyperactivityGlaxoSmithKline · NCT00048360 · 162 enrolled · United States
- Jan 7, 20032 phase 3 studies in Depressive Disorder, MajorGlaxoSmithKline · NCT00051272, NCT00051259
- Sep 25, 2003Phase 1 study in Depressive DisorderGlaxoSmithKline · NCT00069459 · 250 enrolled · United States
- Oct 5, 2004Phase 3 study in Depressive Disorder, MajorGlaxoSmithKline · NCT00093288 · 364 enrolled · Australia, Belgium, Finland and more
- Aug 24, 2005Phase 2 study in Depressive DisorderGlaxoSmithKline · NCT00135512 · 234 enrolled · Japan
- Mar 17, 2009Teva Pharmaceutical Industries's first studies: 5 phase 1 studies in HealthyNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT00865462, NCT00865410, NCT00865371 and 2 more
- Apr 16, 2009Novartis's first study: phase 1 study in HealthyNew to NovartisNovartis · NCT00883155 · 36 enrolled
- Jan 8, 2010Phase 1 study in Depressive DisorderTeva Pharmaceutical Industries · NCT01046214 · 8 enrolled · United States
- Jul 14, 2014Phase 3 study in Depressive Disorder, MajorGlaxoSmithKline · NCT02191397 · 534 enrolled · China
- Oct 2, 2015Johnson & Johnson's first study: phase 1 study in HealthyNew to Johnson & JohnsonJohnson & Johnson · NCT02568176 · 71 enrolled · Belgium
- Nov 24, 2015Takeda's first study: phase 4 study in Weight Regain Post Bariatric SurgeryNew to TakedaTakeda · NCT02616315 · United States
- May 11, 2020Rose Research Center's first study: phase 3 study in Smoking CessationNew to Rose Research CenterRose Research Center · NCT04388319 · 26 enrolled · United States
- Oct 27, 2021Phase 3 study in Smoking CessationRose Research Center · NCT05205811 · 180 enrolled · United States
TargetBeta
“Dopamine transporter inhibitor; Dopamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lisdexamfetaminerule | Takeda | phase 4 | 47 |
| dexmethylphenidaterule | cingulate-therapeutics | phase 4 | 14 |
| Amphetaminerule | Tris Pharma | phase 4 | 8 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT05205811Smoking Cessation · United States | 3 | Completed | Rose Research Center | Jun 19, 2025 | 180 |
| NCT04388319Smoking Cessation · United States | 3 | Completed | Rose Research Center | Jun 4, 2021 | 26 |
| NCT02616315Weight Regain Post Bariatric Surgery · United States | 4 | Withdrawn | Takeda | Oct 2017 | 0 |
| NCT02568176Healthy · Belgium | 1 | Completed | Johnson & Johnson | Feb 2016 | 71 |
| NCT02191397Depressive Disorder, Major · China | 3 | Completed | GlaxoSmithKline | Oct 10, 2016 | 534 |
| NCT01046214Depressive Disorder · United States | 1 | Terminated | Teva Pharmaceutical Industries | 8 | |
| NCT00883155Healthy | 1 | Completed | Novartis | Oct 1998 | 36 |
| NCT00865462Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jul 2004 | 30 |
| NCT00865410Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2004 | 26 |
| NCT00865371Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Sep 2004 | 26 |
| NCT00865111Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Apr 2006 | 26 |
| NCT00863941Healthy · United States | 1 | Completed | Teva Pharmaceutical Industries | Jul 2004 | 28 |
| NCT00135512Depressive Disorder · Japan | 2 | Completed | GlaxoSmithKline | May 28, 2007 | 234 |
| NCT00093288Depressive Disorder, Major · Australia, Belgium, Finland and more | 3 | Completed | GlaxoSmithKline | Oct 2005 | 364 |
| NCT00069459Depressive Disorder · United States | 1 | Completed | GlaxoSmithKline | Jun 3, 2004 | 250 |
| NCT00051272Depressive Disorder, Major · United States | 3 | Completed | GlaxoSmithKline | Jun 2004 | 425 |
| NCT00051259Depressive Disorder, Major · United States | 3 | Completed | GlaxoSmithKline | Jun 2004 | 420 |
| NCT00048360Attention Deficit Disorder with Hyperactivity · United States | 3 | Completed | GlaxoSmithKline | Jun 2003 | 162 |
| NCT00046241Seasonal Affective Disorder · United States, Canada | 3 | Completed | GlaxoSmithKline | Jun 2003 | 300 |
How it is read
Names in the registry
- “Bupropion”, 7 entries
- “bupropion hydrochloride”, 3 entries
- “Extended-release Bupropion Hydrochloride”, 2 entries
- “Extended-release bupropion hydrochloride”, 2 entries
- “Bupropion HCl”, 2 entries
Conditions, from the studies’ own filings
- Smoking Cessation, 5 studies
- Depressive Disorder, Major, 4 studies
- Depressive Disorder, 2 studies
- Seasonal Affective Disorder, 2 studies
- Obesity, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.